| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|---|---|---|---|---|---|
Revenue: | ||||||
Contract research revenue | ||||||
89 | 119 | - | - | - | - | - |
Contract research revenue | ||||||
- | - | 149 | 0 | 194 | 0 | - |
Research and development | ||||||
11,234 | 6,787 | 9,010 | 3,947 | 5,292 | 5,175 | 1,761 |
General and administrative | ||||||
7,776 | 7,978 | 7,641 | 4,309 | 4,813 | 5,289 | 1,950 |
Total costs and expenses | ||||||
19,010 | 14,766 | 16,652 | 8,257 | 10,105 | - | - |
Total costs and expenses | ||||||
- | - | - | - | - | 10,464 | 3,712 |
Loss from operations | ||||||
-18,921 | -14,646 | -16,502 | -8,257 | -9,911 | -10,464 | -3,712 |
Sale of New Jersey net operating loss | ||||||
1,007 | - | 636 | 674 | 756 | 269 | 0 |
Other income, net | ||||||
541 | 56 | 22 | -16 | 19 | -25 | -0 |
Benefit for income taxes | ||||||
- | 506 | -356 | 0 | 0 | - | - |
Net loss | ||||||
-17,372 | -14,083 | -15,486 | -7,598 | -9,135 | -10,221 | -3,713 |
Preferred stock series A accumulated dividends | ||||||
338 | 587 | 608 | - | - | - | - |
Preferred stock series B accumulated dividends | ||||||
585 | 317 | - | - | - | - | - |
Dividend to preferred shareholders | ||||||
- | - | - | 0 | 0 | - | - |
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend | ||||||
- | - | - | 4,393 | 0 | - | - |
Inducement charge from exercise of warrants | ||||||
- | - | -16,741 | 0 | 0 | - | - |
Net loss attributable to common shareholders | ||||||
-18,296 | -14,988 | -32,836 | -11,992 | -9,135 | - | - |
Net loss attributable to common shareholders per share - basic and diluted | ||||||
-0.13 | -0.15 | -0.36 | -0.21 | -0.18 | -0.32 | -0.20 |
Weighted average common shares outstanding: | ||||||
Basic and diluted | ||||||
145,195 | 98,103 | 90,475 | 57,654 | 51,481 | 32,076 | 19,001 |
Other comprehensive income/(loss), net of tax | ||||||
Unrealized gain on securities available-for-sale | ||||||
0 | - | - | - | - | - | - |
Other comprehensive income/(loss), net of tax | ||||||
-0 | - | - | - | - | - | - |
Comprehensive loss attributable to shareholders | ||||||
-17,373 | -14,083 | - | - | - | - | - |